Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings

AQST·Reported May 13, 2026·After market close

Aquestive Therapeutics, Inc. reported Q1 2026 revenue of $14.4M (+65.7% YoY), beat analyst consensus of $10.9M by $3.6M. Diluted EPS came in at $-0.07 (+70.8% YoY), beat the $-0.14 consensus by $0.07.

Revenue
$14.4Mbeat by $3.6M
Consensus: $10.9M
Diluted EPS
$-0.07beat by $0.07
Consensus: $-0.14
SEC

SEC Filings

Earnings release8-K · 0001398733-26-000029
Quarterly report10-Q · 0001398733-26-000030

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Aquestive Therapeutics, Inc.'s Q1 2026 earnings report.

Aquestive Therapeutics, Inc. (AQST) reported Q1 2026 earnings on May 13, 2026 after market close.

Aquestive Therapeutics, Inc. reported revenue of $14.4M and diluted EPS of $-0.07 for Q1 2026.

Revenue beat the consensus estimate of $10.9M by $3.6M. EPS beat the consensus estimate of $-0.14 by $0.07.

Compared to the same quarter a year prior, revenue grew 65.7% from $8.7M a year earlier and diluted EPS grew 70.8% from $-0.24.

You can read the 8-K earnings release (0001398733-26-000029) and the 10-Q periodic report (0001398733-26-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.